✦ LIBER ✦

A randomized phase II study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy

✍ Scribed by W. Yeo; F.K.F. Mo; J.J.S. Suen; W.M. Ho; S.L. Chan; W.K. Yeung; W. Lau; K.K.C. Lee; W.H. Kwan; B. Zee

Book ID: 119598305
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 58 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)70813-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized study of aprepitant, ondans

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy

✍ Winnie Yeo; F. K. F. Mo; J. J. S. Suen; W. M. Ho; S. L. Chan; W. Lau; J. Koh; W. 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 184 KB

9048 Aprepitant for the prevention of ch

9048 Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer

✍ Rapoport, B.; Boice, J.A.; Brown, C.; Street, J.C.; Hardwick, J.S.; Carides, A.D 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 67 KB

57LBA Aprepitant (APR) for the preventio

57LBA Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) in breast and non-breast cancers

✍ R. Gralla; B. Rapoport; C. Brown; J.C. Street; J.S. Hardwick; A.D. Carides 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Olanzapine for the Prevention of Chemoth

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study

✍ Mizukami, Naomi; Yamauchi, Masanori; Koike, Kazuhiko; Watanabe, Akihiko; Ichihar 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 243 KB

Phase 2 trial results with the novel neu

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

✍ Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views

Aprepitant for the prevention of chemoth

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

✍ Bernardo L. Rapoport; Karin Jordan; Judith A. Boice; Arlene Taylor; Carole Brown 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 174 KB